Yuhong Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuhong Jiang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Canquan Mao
Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs School of Life Science and Engineering Southwest Jiaotong University Chengdu People's Republic of China
9 shared publicationsShanshan Qi
Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs School of Life Science and Engineering Southwest Jiaotong University Chengdu People's Republic of China
5 shared publications- Xun Sun
Sichuan University
5 shared publications Zhirong Zhang
Key Laboratory of Drug Targeting, Ministry of Education, West China School of Pharmacy, Sichuan University , Chengdu, 610041, People's Republic of China
5 shared publications- David P. Fairlie
Centre for Chemistry and Drug Discovery Institute for Molecular Bioscience The University of Queensland Brisbane Queensland Australia
4 shared publications - Jacky Y. Suen
The University of Queensland
4 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Advanced Science
Trypsin Digestion Impacts Cellular Functions and Drug Efficacy Evaluation via PAR2/NLRP3 Signaling
Trypsin acts as a standard digestive reagent for cell dissociation and passaging in biomedical research. In addition to its role in proteolytic detachment, trypsin activates protease‐activated receptor 2 (PAR2), a member of the G protein‐coupled receptor, thereby initiating downstream signaling. However, the impact of this unintended PAR2 activation on regulating cellular functions, and its consequent influence on drug candidate evaluation in cell‐based assays, has long been overlooked. Here, we demonstrated that trypsin‐mediated dissociation, unlike EDTA treatment or mechanical pipetting, potently enhanced cell adhesion, migration, and proliferation across multiple cell types in vitro, and accelerated tumor growth in vivo, primarily via PAR2 signaling. Moreover, trypsin digestion compromised the anti‐migratory and anti‐tumor efficacy of sorafenib, which could be effectively rescued by PAR2 knockout. Importantly, trypsin‐induced PAR2 activation acted as a cumulative proinflammatory stimulus, which peaked at 24 h post‐treatment, and facilitated EMT, adhesion, migration, and tumor growth, mechanistically through the NLRP3/caspase‐1/IL‐1β/IL‐18 pathway. Collectively, it revealed a previously unrecognized signaling mechanism by which routine trypsin digestion modulated fundamental cellular behaviors and biased drug efficacy evaluation. The potential confounding effects of PAR2 activation triggered by trypsin dissociation should be carefully considered—and minimized where possible—in experimental design and data analysis within biological and pharmaceutical research.
- 15 November 2026
- Published by Wiley in Advanced Science
Open AccessTrypsin Digestion Impacts Cellular Functions and Drug Efficacy Evaluation via PAR2/NLRP3 Signaling
Trypsin acts as a standard digestive reagent for cell dissociation and passaging in biomedical research. In addition to its role in proteolytic detachment, trypsin activates protease‐activated receptor 2 (PAR2), a member of the G protein‐coupled receptor, thereby initiating downstream signaling. However, the impact of this unintended PAR2 activation on regulating cellular functions, and its consequent influence on drug candidate evaluation in cell‐based assays, has long been overlooked. Here, we demonstrated that trypsin‐mediated dissociation, unlike EDTA treatment or mechanical pipetting, potently enhanced cell adhesion, migration, and proliferation across multiple cell types in vitro, and accelerated tumor growth in vivo, primarily via PAR2 signaling. Moreover, trypsin digestion compromised the anti‐migratory and anti‐tumor efficacy of sorafenib, which could be effectively rescued by PAR2 knockout. Importantly, trypsin‐induced PAR2 activation acted as a cumulative proinflammatory stimulus, which peaked at 24 h post‐treatment, and facilitated EMT, adhesion, migration, and tumor growth, mechanistically through the NLRP3/caspase‐1/IL‐1β/IL‐18 pathway. Collectively, it revealed a previously unrecognized signaling mechanism by which routine trypsin digestion modulated fundamental cellular behaviors and biased drug efficacy evaluation. The potential confounding effects of PAR2 activation triggered by trypsin dissociation should be carefully considered—and minimized where possible—in experimental design and data analysis within biological and pharmaceutical research.
- Open Access
- 12 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (34) , e71584
A Fluorinated Dual‐Functional Nanoassembly Induces Potent Antitumor Immunity via Programmable PD‐L1 Suppression
Antibody‐mediated blockade of the PD‐1/PD‐L1 immune checkpoint has revolutionized cancer treatment. However, their efficacy is often limited by the compensatory upregulation of PD‐L1 synthesis, which sustains surface expression upon blockade. FOXM1, a pivotal oncogenic transcription factor overexpressed in diverse cancers, directly transactivates PD‐L1 expression, presenting a strategic upstream therapeutic target. To concurrently suppress both membrane‐bound and newly synthesized intracellular PD‐L1, we modularly designed a dual‐functional nanoassembly via the co‐assembly of a fluorinated FOXM1‐inhibitory peptide and a PD‐L1‐targeting aptamer. This nanoassembly leverages fluorination to enhance nanoassembly stability and cytosolic delivery efficiency to achieve a programmable two‐stage PD‐L1 suppression. The aptamer module mediates tumor‐targeted binding and blocks surface PD‐L1, after which the internalized nanoassembly releases the peptide module to transcriptionally suppress PD‐L1 via FOXM1 inhibition. Consequently, this nanoassembly achieves potent PD‐L1 downregulation, addressing the limitations of conventional antibody blockade that primarily targets surface proteins. In murine models, this dual‐inhibition strategy robustly reinvigorates antitumor immunity, significantly suppressing tumor growth and metastasis. Our work establishes a dual‐functional nanoassembly that programmably controls PD‐L1 expression, presenting a promising approach to circumvent adaptive resistance in cancer immunotherapy by durably targeting the source of PD‐L1 expression.
- 12 August 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (34) , e71584
Open AccessA Fluorinated Dual‐Functional Nanoassembly Induces Potent Antitumor Immunity via Programmable PD‐L1 Suppression
Antibody‐mediated blockade of the PD‐1/PD‐L1 immune checkpoint has revolutionized cancer treatment. However, their efficacy is often limited by the compensatory upregulation of PD‐L1 synthesis, which sustains surface expression upon blockade. FOXM1, a pivotal oncogenic transcription factor overexpressed in diverse cancers, directly transactivates PD‐L1 expression, presenting a strategic upstream therapeutic target. To concurrently suppress both membrane‐bound and newly synthesized intracellular PD‐L1, we modularly designed a dual‐functional nanoassembly via the co‐assembly of a fluorinated FOXM1‐inhibitory peptide and a PD‐L1‐targeting aptamer. This nanoassembly leverages fluorination to enhance nanoassembly stability and cytosolic delivery efficiency to achieve a programmable two‐stage PD‐L1 suppression. The aptamer module mediates tumor‐targeted binding and blocks surface PD‐L1, after which the internalized nanoassembly releases the peptide module to transcriptionally suppress PD‐L1 via FOXM1 inhibition. Consequently, this nanoassembly achieves potent PD‐L1 downregulation, addressing the limitations of conventional antibody blockade that primarily targets surface proteins. In murine models, this dual‐inhibition strategy robustly reinvigorates antitumor immunity, significantly suppressing tumor growth and metastasis. Our work establishes a dual‐functional nanoassembly that programmably controls PD‐L1 expression, presenting a promising approach to circumvent adaptive resistance in cancer immunotherapy by durably targeting the source of PD‐L1 expression.
- 26 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117932
Deciphering the immunomodulatory code: how metal nanoadjuvants orchestrate intracellular immune signaling cascades
- 26 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117932
Deciphering the immunomodulatory code: how metal nanoadjuvants orchestrate intracellular immune signaling cascades
- 1 March 2026
- Published by Taylor & Francis in Innovation in Language Learning and Teaching
- p. 1-19
How do language teachers’ emotions matter? Examining the relationships between emotion regulation strategies, teaching enjoyment, resilience, and work engagement in the multilingual context
1. Teaching multilingual students poses significant emotional challenges and responsibilities for language teachers, also in the context of Chinese as second language (CSL), which demands a lot of ...
- 1 March 2026
- Published by Taylor & Francis in Innovation in Language Learning and Teaching
- p. 1-19
How do language teachers’ emotions matter? Examining the relationships between emotion regulation strategies, teaching enjoyment, resilience, and work engagement in the multilingual context
1. Teaching multilingual students poses significant emotional challenges and responsibilities for language teachers, also in the context of Chinese as second language (CSL), which demands a lot of ...
- 31 October 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178311
GPCR signaling from endosome: mechanistic insights and therapeutic potentials
- 31 October 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178311
GPCR signaling from endosome: mechanistic insights and therapeutic potentials
- 23 June 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 240, 117064
Identification and characterization of a potent peptide inhibitor targeting FOXM1 in cancer therapy
- 23 June 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 240, 117064
Identification and characterization of a potent peptide inhibitor targeting FOXM1 in cancer therapy
- Open Access
- 7 March 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (4) , 1796-1815
Polysaccharide nanoparticles as potential immune adjuvants: Mechanism and function
- 7 March 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (4) , 1796-1815
Open AccessPolysaccharide nanoparticles as potential immune adjuvants: Mechanism and function
- 4 January 2025
- Published by Elsevier in Biomaterials
- Vol. 317, 123090
Nano-polymeric platinum activates PAR2 gene editing to suppress tumor metastasis
- 4 January 2025
- Published by Elsevier in Biomaterials
- Vol. 317, 123090
Nano-polymeric platinum activates PAR2 gene editing to suppress tumor metastasis
Dual‐functional Nanosized Albumin Facilitates CRISPR‐Cas9‐PAR2 to Mitigate Cytokine Storm via TLR4 and Pyroptosis Signaling
Protease‐activated receptor 2 (PAR2) widely modulates various cytokine secretions and inflammatory responses, while excessive cytokine releases and immune hyperactivation may trigger cytokine storm. However, the potential participation of PAR2 in cytokine storm remains elusive. CRISPR‐Cas9 as an efficient gene editing tool can be used for investigating the possible function of PAR2. In this study, albumin‐based nanoparticles (hAlbumin/cgPAR2) to protect and deliver CRISPR‐Cas9 for precise gene editing of PAR2 is constructed. Nanosized albumin largely assisted CRISPR‐Cas9‐PAR2 (cgPAR2) to enter cells via scavenger receptor‐mediated endocytosis, and then triggered potent transfection efficiency, consequently stimulating PAR2 knockout in vitro and in vivo. Apart from delivering CRISPR‐Cas9, nanosized albumin could be colocalized with TLR4 on endosome and promote PAR2 deficiency to attenuate TLR4/NF‐κB signaling, exerting the strong inhibitory effect of albumin in inflammatory responses depending on TLR4. Moreover, PAR2 deficiency induced by hAlbumin/cgPAR2 alleviated ERK/STING/NLRP3 signaling and GSDMD‐mediated pyroptosis, consequently inhibiting cytokine storm. Therefore, this study uncovered dual functions of nanosized albumin in delivering CRISPR‐Cas9 and facilitating PAR2 deficiency to prevent cytokine storm. It also uncovered that the significant role of PAR2 in modulating cytokine storm and provided a potential gene therapy strategy for treating this disease.
Dual‐functional Nanosized Albumin Facilitates CRISPR‐Cas9‐PAR2 to Mitigate Cytokine Storm via TLR4 and Pyroptosis Signaling
Protease‐activated receptor 2 (PAR2) widely modulates various cytokine secretions and inflammatory responses, while excessive cytokine releases and immune hyperactivation may trigger cytokine storm. However, the potential participation of PAR2 in cytokine storm remains elusive. CRISPR‐Cas9 as an efficient gene editing tool can be used for investigating the possible function of PAR2. In this study, albumin‐based nanoparticles (hAlbumin/cgPAR2) to protect and deliver CRISPR‐Cas9 for precise gene editing of PAR2 is constructed. Nanosized albumin largely assisted CRISPR‐Cas9‐PAR2 (cgPAR2) to enter cells via scavenger receptor‐mediated endocytosis, and then triggered potent transfection efficiency, consequently stimulating PAR2 knockout in vitro and in vivo. Apart from delivering CRISPR‐Cas9, nanosized albumin could be colocalized with TLR4 on endosome and promote PAR2 deficiency to attenuate TLR4/NF‐κB signaling, exerting the strong inhibitory effect of albumin in inflammatory responses depending on TLR4. Moreover, PAR2 deficiency induced by hAlbumin/cgPAR2 alleviated ERK/STING/NLRP3 signaling and GSDMD‐mediated pyroptosis, consequently inhibiting cytokine storm. Therefore, this study uncovered dual functions of nanosized albumin in delivering CRISPR‐Cas9 and facilitating PAR2 deficiency to prevent cytokine storm. It also uncovered that the significant role of PAR2 in modulating cytokine storm and provided a potential gene therapy strategy for treating this disease.
- Open Access
- 29 December 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (2) , 105614
New insight into the agonism of protease-activated receptors as an immunotherapeutic strategy
- 29 December 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (2) , 105614
Open AccessNew insight into the agonism of protease-activated receptors as an immunotherapeutic strategy